Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Xiaomeng Zou"'
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor as a third-line and subsequent treatment for patients with small cell lung cancer (SCLC) in China. The neurotoxicity is less reported. Posterior reversible encephalopathy syndrome (PRES) i
Externí odkaz:
https://doaj.org/article/992d79dc37f84fc3ac394adad0cfcfd9
Autor:
Tianxiu Dong, Jian Jiang, Hao Zhang, Hongyuan Liu, Xiaomeng Zou, Jiamei Niu, Yingxuan Mao, Mingwei Zhu, Xi Chen, Zizhuo Li, Yaodong Chen, Chunying Shi, Xiuhua Yang
Publikováno v:
Nano Convergence, Vol 8, Iss 1, Pp 1-16 (2021)
Abstract Hepatocellular carcinoma (HCC) is one of the most malignant tumors in the world, and patients with HCC face a poor prognosis. The conventional therapeutic strategies for HCC have undergone a challenge-riddled evolution owing to side effects
Externí odkaz:
https://doaj.org/article/03e74595479f4aae83f9b6793fe14d7d
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundPD-1/PD-L1 inhibitors have significantly improved the outcomes of those patients with various malignancies. However, the incidence of adverse events also increased. This meta-analysis aims to systematically evaluate the risk of cardiovascul
Externí odkaz:
https://doaj.org/article/a8d9b9f8d3144ece91348aeadb24b2d2
Autor:
Hao Zhang, Yingxuan Mao, Xiaomeng Zou, Jiamei Niu, Jian Jiang, Xi Chen, Mingwei Zhu, Xiuhua Yang, Tianxiu Dong
Publikováno v:
Neoplasma. 70:94-102
Autor:
Xiaomeng Zou, Tiantian Li, Yingxuan Mao, Mingwei Zhu, Xi Chen, Jiamei Niu, Tianxiu Dong, Jian Jiang, Xiuhua Yang
Publikováno v:
BioMed research international. 2022
Objectives. Preparation of a multifunctional drug-loaded phase-change nanoparticle (NP), pirfenidone perfluoropentane liposome NPs (PPL NPs), and combined with low-intensity focused ultrasound (LIFU) to influence epithelial mesenchymal transition (EM
Autor:
Tianxiu, Dong, Jian, Jiang, Hao, Zhang, Hongyuan, Liu, Xiaomeng, Zou, Jiamei, Niu, Yingxuan, Mao, Mingwei, Zhu, Xi, Chen, Zizhuo, Li, Yaodong, Chen, Chunying, Shi, Xiuhua, Yang
Publikováno v:
Nano Convergence
Hepatocellular carcinoma (HCC) is one of the most malignant tumors in the world, and patients with HCC face a poor prognosis. The conventional therapeutic strategies for HCC have undergone a challenge-riddled evolution owing to side effects and unsat